I’m not here for $.46 five years from now that’s my point …..I’m wanting to see a dollar within the next year at the minimum, It went from a penny to $.22 basically on just speculation, no real news So I don’t think a dollar Is out of the question if we have successful trials of Met Forman we should be at 20 or $.30 just off the news that we’re starting clinical trials
Senior Investigator at The National Institutes of Health 1w
Excited to work with Curative Biotech on evaluating metformin eye drops as a potential treatment for retinal degenerative diseases. This technology showed promising results in preclinical studies performed using patient stem cell derived eye cells. Two publications on the way.
3 Replies on Kapil Bharti’s comment
See profile for Rajarshi Pal, Ph.D.
Chief Scientist, Eyestem Research, Centre for Cellular and Molecular Platforms (C-CAMP), NCBS-TIFR Campus, Bangalore
1w That’s amazing news! Metformin is a pleiotropic molecule and unsurprisingly there is evidence of its therapeutic potential in AMD patients, through retrospective trials. However knowing the mechanism would be exciting- perhaps through its role as a TGF-beta inhibitor!??
See profile for Kapil Bharti Kapil Bharti
Senior Investigator at The National Institutes of Health 1w
Rajarshi Pal, Ph.D. Thanks Raj! As your said, it’s a pleiotropic molecule. We see effects on lipid metabolism, mitochondrial function, cell polarity, and EMT.
Rajarshi Pal, Ph.D.
Chief Scientist, Eyestem Research, Centre for Cellular and Molecular Platforms (C-CAMP), NCBS-TIFR Campus, Bangalore
6d Kapil Bharti Wow, sounds very interesting! Earlier, we too had identified the role of metformin in type 1 and type 3 EMT using stem cell lines and validated the mechanisms in an animal model and patients respectively.
Market Data 
Markets 
AI
